Showing results (71-80 of 368) with videos related to
Sort By:
Pageof 37
Cancer Causes & Control : CCC|September 30, 2016
Should low-income countries invest in breast cancer screening?Bishal Gyawali, Tomoya Shimokata, Kazunori Honda, et al.Eclinicalmedicine|March 8, 2021
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancerBishal Gyawali, Elvira D'Andrea, Jessica M Franklin, et al.Chest|October 10, 2024
A 63-Year-Old Presents With Acute Fatigue, Dyspnea, and HypoxiaEric Merrell, Louis Arens, Bishal Gyawali, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 6, 2021
An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on AccessNatasha B Leighl, Sharon Nirmalakumar, Doreen A Ezeife, et al.Eclinicalmedicine|November 29, 2022
Objective response rate of placebo in randomized controlled trials of anticancer medicinesArushi Sachdev, Isobel Sharpe, Meghan Bowman, et al.JAMA Internal Medicine|February 22, 2021
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated ApprovalAvi Cherla, Huseyin Naci, Aaron S Kesselheim, et al.Eclinicalmedicine|January 7, 2025
Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forwardAbhenil Mittal, Myung Sun Kim, Shenna Dunn, et al.Journal for Immunotherapy of Cancer|September 5, 2020
Tracking the tailAlex Friedlaender, Stephen V Liu, Alfredo AddeoCancers|June 2, 2021
KRAS G12C Mutations in NSCLC: From Target to ResistanceAlfredo Addeo, Giuseppe Luigi Banna, Alex FriedlaenderJAMA Network Open|August 31, 2019
Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled AnalysisBishal Gyawali, Frazer A Tessema, Emily H Jung, et al.Pageof 37